Top

Published in:

31-08-2021 | Chronic Inflammatory Bowel Disease | Original Article

Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease

Authors: Masayoshi Sato, Kazuyuki Fujii, Hiroko Takagi, Isao Shibuya, Daisuke Oka, Naomitsu Yamaya, Hiraku Hagita, Makoto Matsumoto, Katsuya Inagaki

Published in: Digestive Diseases and Sciences | Issue 8/2022

Abstract

Background

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. Although many types of drug are used, clinical outcomes are still unsatisfactory. Previous studies have suggested that intestinal bacteria are involved in the pathogenesis of IBD. Accordingly, in an IBD model we evaluated the therapeutic effects of OPS-2071, a low-absorption quinolone antibacterial agent indicated for intestinal infection, and investigated its mechanism of action.

Methods

The therapeutic effects of OPS-2071 and comparison therapies were evaluated using naive CD4 + T cell-transfer IBD model mice. In vitro inhibition of LPS-induced TNF-α production and inhibitory effects on T cell responses stimulated using anti-CD3/CD28 antibody-loaded beads were evaluated using mouse splenocytes and human peripheral blood mononuclear cells. In addition, in vitro activities against bacteria implicated in IBD pathogenesis were tested.

Results

OPS-2071 dose-dependently decreased both colonic weight/length ratio and the colitis histological score as compared with the vehicle group. The therapeutic effect of OPS-2071 was equivalent to that of anti-IL-12/23 (p40) antibody. In vitro, OPS-2071 suppressed TNF-α production induced by LPS stimulation and T cell responses in a dose-dependent manner. At high concentrations, these effects were comparable to those of existing immunosuppressive agents, such as prednisolone, in both mouse and human cells. OPS-2071 also showed antibacterial activity against IBD-related bacteria.

Conclusions

Our results suggest that OPS-2071 had both immunosuppressive and antibacterial effects. This dual effect makes OPS-2071 a unique and promising candidate for IBD.

Available only for authorised users

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet. 2007;369:1641–1657. https://doi.org/10.1016/s0140-6736(07)60751-x.CrossRef

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. The Lancet. 2007;369:1627–1640. https://doi.org/10.1016/s0140-6736(07)60750-8.CrossRef

Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017;152:313-321e2. https://doi.org/10.1053/j.gastro.2016.10.020.CrossRefPubMed

Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14:573–584. https://doi.org/10.1038/nrgastro.2017.88.CrossRefPubMedPubMedCentral

Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG et al. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019;79:1321–1335. https://doi.org/10.1007/s40265-019-01169-y.CrossRefPubMed

Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2016;7(7):CD008870. https://doi.org/10.1002/14651858.CD008870.pub2.CrossRefPubMed

Warner B, Johnston E, Arenas-Hernandez M, Marinaki A, Irving P, Sanderson J. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. 2018;9:10–15. https://doi.org/10.1136/flgastro-2016-100738.CrossRefPubMed

Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J et al. Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS One. 2016;11:e0158017. https://doi.org/10.1371/journal.pone.0158017.CrossRefPubMedPubMedCentral

Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767. https://doi.org/10.1038/ajg.2008.88.CrossRefPubMed

10.

Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T et al. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis. 2019;4:79–96. https://doi.org/10.1159/000500721.CrossRefPubMedPubMedCentral

11.

Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis. 2019;25:820–830. https://doi.org/10.1093/ibd/izy327.CrossRefPubMed

12.

Fiocchi C, Iliopoulos D. What’s new in IBD therapy: An “omics network” approach. Pharmacol Res. 2020;159:104886. https://doi.org/10.1016/j.phrs.2020.104886.CrossRefPubMed

13.

Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342. https://doi.org/10.1038/nri3661.CrossRefPubMed

14.

Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol. 2011;17:4643–4646. https://doi.org/10.3748/wjg.v17.i42.4643.CrossRefPubMedPubMedCentral

15.

Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010;50:473–480. https://doi.org/10.1086/649923.CrossRefPubMed

16.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52:2920–2925. https://doi.org/10.1007/s10620-007-9760-1.CrossRefPubMed

17.

Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000;15:61–68. https://doi.org/10.1046/j.1440-1746.2000.02045.x.CrossRefPubMed

18.

Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017;358:359–365. https://doi.org/10.1126/science.aan4526.CrossRefPubMedPubMedCentral

19.

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17:1971–1978. https://doi.org/10.1002/ibd.21606.CrossRefPubMed

20.

McNees AL, Markesich D, Zayyani NR, Graham DY. Mycobacterium paratuberculosis as a cause of Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2015;9:1523–1534. https://doi.org/10.1586/17474124.2015.1093931.CrossRefPubMedPubMedCentral

21.

Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8:1–6. https://doi.org/10.5009/gnl.2014.8.1.1.CrossRefPubMedPubMedCentral

22.

Tariq R, Law CCY, Khanna S, Murthy S, McCurdy JD. The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019;53:127–133. https://doi.org/10.1097/MCG.0000000000000968.CrossRefPubMed

23.

Oka D, Yamaya N, Kuno T, Asakawa Y, Shiragiku T, Chen L et al. In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile. Antimicrob Agents Chemother. 2021;65(4). doi:https://doi.org/10.1128/AAC.01170-20.

24.

ClinicalTrials.gov. A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis. 2021. Available at: https://clinicaltrials.gov/ct2/show/results/NCT02473393?term=ops-2071&draw=2&rank=3. Accessed 29 Mar 2021.

25.

Douros A, Grabowski K, Stahlmann R. Safety issues and drug-drug interactions with commonly used quinolones. Expert Opin Drug Metab Toxicol. 2015;11:25–39. https://doi.org/10.1517/17425255.2014.970166.CrossRefPubMed

26.

ClinicalTrials.gov. OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01925521?term=ops-2071&draw=2&rank=1. Accessed 29 Mar 2021.

27.

Kjellev S, Lundsgaard D, Poulsen SS, Markholst H. Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. Int Immunopharmacol. 2006;6:1341–1354. https://doi.org/10.1016/j.intimp.2006.04.017.CrossRefPubMed

28.

Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol. 1996;148:1503–15.PubMedPubMedCentral

29.

Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296:G135–G146.CrossRef

30.

Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. The Lancet Infectious Diseases. 2003;3:359–371. https://doi.org/10.1016/s1473-3099(03)00658-3.CrossRefPubMed

31.

te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:325–330. https://doi.org/10.1002/ibd.20079.CrossRef

32.

Kim JM, Kang HW, Cha MY, Yoo D, Kim N, Kim IK et al. Novel guggulsterone derivative GG-52 inhibits NF-kappaB signaling in intestinal epithelial cells and attenuates acute murine colitis. Lab Invest. 2010;90:1004–1015. https://doi.org/10.1038/labinvest.2010.54.CrossRefPubMed

33.

Ge F, Zhu S, Liu L, Yan J, Ji Y, Sun Z. Anti-inflammatory effects of Fagopyrum cymosum administered as a potential drug for ulcerative colitis. Exp Ther Med. 2017;14:4745–4754. https://doi.org/10.3892/etm.2017.5153.CrossRefPubMedPubMedCentral

34.

Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJ et al. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A. 2002;99:15770–15775. https://doi.org/10.1073/pnas.232583599.CrossRefPubMedPubMedCentral

35.

Min B, Spontaneous T. Cell Proliferation: A Physiologic Process to Create and Maintain Homeostatic Balance and Diversity of the Immune System. Front Immunol. 2018;9:547. https://doi.org/10.3389/fimmu.2018.00547.CrossRefPubMedPubMedCentral

36.

Noguchi D, Wakita D, Tajima M, Ashino S, Iwakura Y, Zhang Y et al. Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol. 2007;19:1431–1440. https://doi.org/10.1093/intimm/dxm114.CrossRefPubMed

37.

Tajima M, Wakita D, Noguchi D, Chamoto K, Yue Z, Fugo K et al. IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med. 2008;205:1019–1027. https://doi.org/10.1084/jem.20071133.CrossRefPubMedPubMedCentral

38.

Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39:49–60. https://doi.org/10.1016/j.immuni.2013.07.002.CrossRefPubMed

39.

Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–728. https://doi.org/10.1038/ni.2366.CrossRefPubMedPubMedCentral

40.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375:1946–1960. https://doi.org/10.1056/NEJMoa1602773.CrossRefPubMed

41.

Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2011;56:376–386. https://doi.org/10.1007/s10620-010-1286-2.CrossRefPubMed

Title: Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease
Authors: Masayoshi Sato
Kazuyuki Fujii
Hiroko Takagi
Isao Shibuya
Daisuke Oka
Naomitsu Yamaya
Hiraku Hagita
Makoto Matsumoto
Katsuya Inagaki
Publication date: 31-08-2021
Publisher: Springer US
Keywords: Chronic Inflammatory Bowel Disease
Ciprofloxacin
Prednisolone
Published in: Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-021-07237-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2022

Loss to Follow-Up and Health Care Utilization After Initial Diagnosis of Eosinophilic Esophagitis

Association Between Immunosuppressive Therapy and Outcome of Clostridioides difficile Infection: Systematic Review and Meta-Analysis

Continuous Infusion of Fluid Hydration Over 24 Hours Does Not Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Predictive Value of Genetic Risk Scores in the Development of Colorectal Adenomas

Lactate Ringer’s Versus Normal Saline in the Management of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page